Abstract
Tumor immunotherapy has entered a phase of rapid development with a shift in emphasis away from classical vaccination approaches against tumor-associated antigens (TAA) towards a focus on various strategies to modify the functions of T cells, as well as to understand and modulate the immunosuppressive nature of tumor microenvironment (TME). With such a paradigm shift, recent international conferences such as "Immune Checkpoint Inhibitors (ICI) Boston" provided unparalleled depth of insights on factors that influence combination efficacy, role of TME, identification of translational biomarkers, latest preclinical modeling approaches, as well as the scientific rationale of targeting novel immune checkpoint pathways. Here I summarize some of the highlights at ICI2017.
Highlights
Tumor immunotherapy has entered a phase of rapid development with a shift in emphasis away from classical vaccination approaches against tumor-associated antigens (TAA) towards a focus on various strategies to modify the functions of T cells, as well as to understand and modulate the immunosuppressive nature of tumor microenvironment (TME)
The annual Immune Checkpoint Inhibitors (ICI) conference has successfully run for the 3rd time in Boston! Defying a late-coming snowstorm in the New England area, participants warmly exchanged fresh data on the success and challenges of checkpoint inhibitors as novel cancer immunotherapy during the meeting on March 15-16, 2017
Tumor immunotherapy has entered a phase of rapid development with a shift in emphasis away from vaccination studies to a focus on various approaches to modify the functions of T cells
Summary
Current Progress in Immune Checkpoint Inhibitors for Cancer Immunotherapy: a Post Event Report of ICI2017. Corresponding Author: Wenda Gao, Antagen Pharmaceuticals , Inc. BioSquare Discovery & Innovation Center 650 Albany Street, Unit 112. Received date: February 15, 2018; Accepted date : March 01, 2018; Published date: March 08, 2018. Citation this Article ; Wenda Gao, Current Progress in Immune Checkpoint Inhibitors for Cancer Immunotherapy: a Post Event Report of ICI2017J Immunology and Inflammation Diseases Therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.